Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brivanib alaninate + 5-fluorouracil + leucovorin + irinotecan
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination comprises **brivanib alaninate** (BMS-582664), an oral prodrug that inhibits vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) tyrosine kinases; **5-fluorouracil** (5-FU), a pyrimidine analogue antimetabolite that inhibits thymidylate synthase; **leucovorin**, which enhances the effects of 5-FU by stabilizing the 5-FU-thymidylate synthase complex; and **irinotecan**, a topoisomerase I inhibitor causing DNA damage. The combination targets angiogenesis, tumor cell proliferation, and DNA replication in cancer cells. Brivanib is under development primarily by Bristol Myers Squibb for advanced/metastatic colorectal cancer and other gastrointestinal malignancies[2][3].
- Other names
- brivanib alaninate + 5-FU + leucovorin + irinotecan
02
Targets
TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)VEGFR-1 (Vascular endothelial growth factor receptor 1)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on brivanib alaninate + 5-fluorouracil + leucovorin + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brivanib alaninate + 5-fluorouracil + leucovorin + irinotecan.